- Home
- ECPG vs MIRM Comparison
ECPG vs MIRM Comparison
Compare ECPG & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECPG
- MIRM
- Stock Information
- Founded
- ECPG 1998
- MIRM 2018
- Country
- ECPG United States
- MIRM United States
- Employees
- ECPG N/A
- MIRM N/A
- Industry
- ECPG Finance Companies
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- ECPG Finance
- MIRM Health Care
- Exchange
- ECPG Nasdaq
- MIRM Nasdaq
- Market Cap
- ECPG N/A
- MIRM 1.9B
- IPO Year
- ECPG 1999
- MIRM 2019
- Fundamental
- Price
- ECPG $34.81
- MIRM $40.00
- Analyst Decision
- ECPG Strong Buy
- MIRM Strong Buy
- Analyst Count
- ECPG 3
- MIRM 11
- Target Price
- ECPG $62.67
- MIRM $58.55
- AVG Volume (30 Days)
- ECPG 327.9K
- MIRM 447.2K
- Earning Date
- ECPG 05-07-2025
- MIRM 05-07-2025
- Dividend Yield
- ECPG N/A
- MIRM N/A
- EPS Growth
- ECPG N/A
- MIRM N/A
- EPS
- ECPG N/A
- MIRM N/A
- Revenue
- ECPG $1,316,361,000.00
- MIRM $336,888,000.00
- Revenue This Year
- ECPG $21.62
- MIRM $29.51
- Revenue Next Year
- ECPG $10.12
- MIRM $20.27
- P/E Ratio
- ECPG N/A
- MIRM N/A
- Revenue Growth
- ECPG 7.66
- MIRM 80.76
- 52 Week Low
- ECPG $26.45
- MIRM $23.14
- 52 Week High
- ECPG $51.77
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- ECPG 55.84
- MIRM 41.05
- Support Level
- ECPG $28.93
- MIRM $38.22
- Resistance Level
- ECPG $30.99
- MIRM $40.14
- Average True Range (ATR)
- ECPG 2.33
- MIRM 2.24
- MACD
- ECPG 0.76
- MIRM 0.07
- Stochastic Oscillator
- ECPG 98.12
- MIRM 48.50
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.